142 related articles for article (PubMed ID: 32616500)
1. T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Vardi A; Vlachonikola E; Papazoglou D; Psomopoulos F; Kotta K; Ioannou N; Galigalidou C; Gemenetzi K; Pasentsis K; Kotouza M; Koravou E; Scarfó L; Iskas M; Stavroyianni N; Ghia P; Anagnostopoulos A; Kouvatsi A; Ramsay AG; Stamatopoulos K; Chatzidimitriou A
Clin Cancer Res; 2020 Sep; 26(18):4958-4969. PubMed ID: 32616500
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
3. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
4. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
[TBL] [Abstract][Full Text] [Related]
5. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Puła B; Długosz-Danecka M; Salomon-Perzyński A; Szymczyk A; Subocz E; Budziszewska BK; Rybka J; Gil L; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Zaucha JM; Osowiecki M; Piszczek W; Steckiewicz P; Szukalski Ł; Hus M; Lech-Marańda E; Jurczak W; Jamroziak K
Adv Med Sci; 2020 Sep; 65(2):371-377. PubMed ID: 32659728
[TBL] [Abstract][Full Text] [Related]
7. EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
Nabergoj S; Markovič T; Avsec D; Gobec M; Podgornik H; Jakopin Ž; Mlinarič-Raščan I
Biochem Pharmacol; 2021 Jan; 183():114352. PubMed ID: 33278351
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Mendicino F; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Cutrona G; Jaksic O; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Eur J Haematol; 2021 Apr; 106(4):493-499. PubMed ID: 33378569
[TBL] [Abstract][Full Text] [Related]
10. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
[TBL] [Abstract][Full Text] [Related]
11. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
[TBL] [Abstract][Full Text] [Related]
12. Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyère H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn LH; Toze CL
Leuk Res; 2021 Apr; 103():106538. PubMed ID: 33647819
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
14. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Fischer K; Bahlo J; Fink AM; Goede V; Herling CD; Cramer P; Langerbeins P; von Tresckow J; Engelke A; Maurer C; Kovacs G; Herling M; Tausch E; Kreuzer KA; Eichhorst B; Böttcher S; Seymour JF; Ghia P; Marlton P; Kneba M; Wendtner CM; Döhner H; Stilgenbauer S; Hallek M
Blood; 2016 Jan; 127(2):208-15. PubMed ID: 26486789
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD
Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982
[TBL] [Abstract][Full Text] [Related]
17. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
18. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
20. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Rossi D; Terzi-di-Bergamo L; De Paoli L; Cerri M; Ghilardi G; Chiarenza A; Bulian P; Visco C; Mauro FR; Morabito F; Cortelezzi A; Zaja F; Forconi F; Laurenti L; Del Giudice I; Gentile M; Vincelli I; Motta M; Coscia M; Rigolin GM; Tedeschi A; Neri A; Marasca R; Perbellini O; Moreno C; Del Poeta G; Massaia M; Zinzani PL; Montillo M; Cuneo A; Gattei V; Foà R; Gaidano G
Blood; 2015 Oct; 126(16):1921-4. PubMed ID: 26276669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
